Thursday Night's Show Highlights:
A biopharma that blocks disease by changing your DNA? Consider Sangamo - SGMO!
Thursday, March 6, 2014
Cramer's comments: (prev. night's show posted each business morning before the market open)
Jim: You call on the Lightning Round and you mention this $12 stock, and sometimes it's kind of interesting, and it's the reason why I tell you to do this, to speculate on tiny-digit stocks with small market caps, is what you're about to hear.
I'm talking about Sangamo BioSciences, SGMO. This is a company that's at the forefront of DNA-based medicine. They're working on therapies that can treat diseases by physically changing your DNA... your DNA... including genetic therapy for HIV that's in Phase II clinical trials that could potentially be a functional cure.
The stock popped $3.35, or 17%, today on the news that the first clinical study of Sangamo's genome-editing technology was just published in the New England Journal of Medicine, which is a major validation of the platform. And the company also presented some major HIV data at a major conference today. Now, I've always believed Sangamo is a game changer. And they're more than just a one-trick pony. The company's also developed treatment for blood disorders like hemophilia and sickle cell anemia, as well as a group of rare orphan diseases known as lyso-somal storage (?) diseases. That said, the stock's already given you a 145% gain since I got behind it 11 months ago. A speculative stock, no doubt about it. Ring the register on at least half of your position if you bought it because of me. Plus, the stock has become controversial of late. Some critics claim that the current standard for HIV - a cocktail of drugs from Gilead - is already pretty darned effective...